Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
Status:
Withdrawn
Trial end date:
2021-10-18
Target enrollment:
Participant gender:
Summary
To determine the recommended phase 2 dose (RP2D) of idelalisib and venetoclax in combination
with rituximab in patients with relapsed or refractory Chronic lymphocytic leukemia/ Small
lymphocytic lymphoma (CLL/SLL) following a lead-in period with idelalisib and rituximab